Unknown
PHASE1
INTERVENTIONAL
NCT02908438
Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.
Interventions
Name:
Gonadotrophin releasing hormone agonist(GnRHa)
Type:
DRUG
Description:
GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
Primary Outcomes
Measure:
pregnancy rate
TimeFrame:
up to 12 months
Description:
Trial Information
NCT ID
NCT02908438
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Last Updated
December 15, 2025